EP3065711A4 - Compositions de transfection sèches et procédés de fabrication et d'utilisation de celles-ci - Google Patents

Compositions de transfection sèches et procédés de fabrication et d'utilisation de celles-ci Download PDF

Info

Publication number
EP3065711A4
EP3065711A4 EP14860556.1A EP14860556A EP3065711A4 EP 3065711 A4 EP3065711 A4 EP 3065711A4 EP 14860556 A EP14860556 A EP 14860556A EP 3065711 A4 EP3065711 A4 EP 3065711A4
Authority
EP
European Patent Office
Prior art keywords
making
methods
same
transfection compositions
dry
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP14860556.1A
Other languages
German (de)
English (en)
Other versions
EP3065711B8 (fr
EP3065711B1 (fr
EP3065711A1 (fr
Inventor
Thomas Patrick Quinn
Sayantan Mitra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takara Bio USA Inc
Original Assignee
Takara Bio USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takara Bio USA Inc filed Critical Takara Bio USA Inc
Publication of EP3065711A1 publication Critical patent/EP3065711A1/fr
Publication of EP3065711A4 publication Critical patent/EP3065711A4/fr
Application granted granted Critical
Publication of EP3065711B1 publication Critical patent/EP3065711B1/fr
Publication of EP3065711B8 publication Critical patent/EP3065711B8/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Manufacturing & Machinery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP14860556.1A 2013-11-05 2014-10-23 Compositions de transfection sèches et procédés de fabrication et d'utilisation de celles-ci Active EP3065711B8 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361900232P 2013-11-05 2013-11-05
PCT/US2014/062011 WO2015069469A1 (fr) 2013-11-05 2014-10-23 Compositions de transfection sèches et procédés de fabrication et d'utilisation de celles-ci

Publications (4)

Publication Number Publication Date
EP3065711A1 EP3065711A1 (fr) 2016-09-14
EP3065711A4 true EP3065711A4 (fr) 2017-06-21
EP3065711B1 EP3065711B1 (fr) 2024-09-04
EP3065711B8 EP3065711B8 (fr) 2024-10-16

Family

ID=53041952

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14860556.1A Active EP3065711B8 (fr) 2013-11-05 2014-10-23 Compositions de transfection sèches et procédés de fabrication et d'utilisation de celles-ci

Country Status (6)

Country Link
US (2) US20160251680A1 (fr)
EP (1) EP3065711B8 (fr)
JP (1) JP6454352B2 (fr)
CN (1) CN105705140A (fr)
CA (1) CA2924013A1 (fr)
WO (1) WO2015069469A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10948412B2 (en) 2015-08-28 2021-03-16 National Institute Of Advanced Industrial Science And Technology Method and system for screening nanoparticle, and nanoparticle and method of producing the same
JP6684557B2 (ja) * 2015-08-28 2020-04-22 国立研究開発法人産業技術総合研究所 ナノ粒子のスクリーニング方法及びスクリーニングシステム
CN110312788A (zh) * 2016-06-21 2019-10-08 江苏大学 一种基于三维体系的细胞重编程方法
WO2019145796A2 (fr) * 2018-01-17 2019-08-01 Aratinga Bio Tnp Vecteurs viraux encapsulés dans un polymère destinés à la thérapie génique

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005055979A2 (fr) * 2003-12-02 2005-06-23 Massachusetts Institute Of Technology Particules polymeres a declenchement en fonction du ph
US6998115B2 (en) * 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US7427394B2 (en) * 2000-10-10 2008-09-23 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US20110008894A1 (en) * 2009-07-07 2011-01-13 Cayla Lyophilized plasmid/dna transfection reagent carrier complex

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US136A (en) 1837-03-03 Mode of molding candles
US5994A (en) 1849-01-02 Combined beading-tool and circular shears
US2217910A (en) 1938-09-23 1940-10-15 Majestic Metal Specialties Inc Vanity case
US5665577A (en) 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5981276A (en) 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
FR2732346B1 (fr) 1995-03-27 1997-05-30 Centre Nat Rech Scient Proteines mutees, codees par un gene env mute de lentivirus, fragments peptidiques inclus dans lesdites proteines, vecteurs d'expression exprimant lesdites proteines mutees et leurs applications
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
CA2287478C (fr) 1997-04-14 2007-06-19 Richard J. Samulski Procede d'amelioration de l'efficacite d'un produit d'aav recombine
US6531123B1 (en) * 1997-05-01 2003-03-11 Lung-Ji Chang Lentiviral vectors
ATE291632T1 (de) 1997-05-13 2005-04-15 Univ North Carolina Auf lentivirus basierende gentransfer-vektoren
CA2303768C (fr) 1997-09-19 2009-11-24 The Trustees Of The University Of Pennsylvania Procedes et produits genetiques vectoriels utiles pour obtenir un virus adeno-associe (aav)
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6953690B1 (en) 1998-03-20 2005-10-11 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
US6740524B1 (en) 1998-06-18 2004-05-25 Dnavec Research, Inc. Nucleic acid transfer phage
JP4693244B2 (ja) 1999-03-18 2011-06-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法
JP3526844B2 (ja) 1999-06-22 2004-05-17 株式会社ディナベック研究所 ２つの外来遺伝子を発現させるためのベクター
US20020006664A1 (en) * 1999-09-17 2002-01-17 Sabatini David M. Arrayed transfection method and uses related thereto
US20040102606A1 (en) * 2001-04-24 2004-05-27 Danuta Balicki Histone H2A -derived peptides useful in gene delivery
US7153622B2 (en) * 2001-04-27 2006-12-26 Canon Kabushiki Kaisha Electrostatic charge image developing toner, producing method therefor, image forming method and image forming apparatus utilizing the toner, construct and method for making the construct
AU2003288686A1 (en) 2002-11-22 2004-06-18 Institut Clayton De La Recherche Compositions and systems for the regulation of genes
US20070269891A9 (en) * 2003-01-13 2007-11-22 Yasunobu Tanaka Solid surface with immobilized degradable cationic polymer for transfecting eukaryotic cells
GB0318704D0 (en) 2003-08-08 2003-09-10 Sirus Pharmaceuticals Ltd Chimaeric vector system
US7943179B2 (en) * 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
WO2005110438A2 (fr) * 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methodes et produits associes de liberation intracellulaire de polysaccharides
US7935811B2 (en) * 2004-11-22 2011-05-03 Dharmacon, Inc. Apparatus and system having dry gene silencing compositions
EP2816118B1 (fr) 2005-05-31 2018-10-17 The Regents of the University of Colorado, a body corporate Procédés pour administrer des gènes
US7863041B2 (en) 2005-10-14 2011-01-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Rabies virus vector systems and compositions and methods thereof
PT3272872T (pt) 2005-10-20 2020-06-26 Uniqure Ip Bv Vetores aav melhorados produzidos em células de insetos
WO2007070392A2 (fr) 2005-12-12 2007-06-21 Canji, Inc. Vecteurs d'expression adenovirale
BRPI0806336A2 (pt) 2006-12-29 2011-09-06 Inst Pasteur Of Shanghai lentivìrus pseudotipado com hemaglutinina da gripe e métodos de uso
US8883493B2 (en) 2007-01-30 2014-11-11 Cedars-Sinai Medical Center Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene
US20100098664A1 (en) 2007-11-28 2010-04-22 Mathieu Jean-Francois Desclaux Lentiviral vectors allowing RNAi mediated inhibition of GFAP and vimentin expression
US8871515B2 (en) 2008-09-17 2014-10-28 Isogenis, Inc. Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof
US9717694B2 (en) * 2009-05-15 2017-08-01 The Johns Hopkins University Peptide/particle delivery systems
US20130136729A1 (en) 2011-11-11 2013-05-30 University of Virginia Patent Foundation, d/b/a University of Virginia Licensing & Ventures Group Compositions and methods for targeting and treating diseases and injuries using adeno-associated virus vectors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6998115B2 (en) * 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US7427394B2 (en) * 2000-10-10 2008-09-23 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
WO2005055979A2 (fr) * 2003-12-02 2005-06-23 Massachusetts Institute Of Technology Particules polymeres a declenchement en fonction du ph
US20110008894A1 (en) * 2009-07-07 2011-01-13 Cayla Lyophilized plasmid/dna transfection reagent carrier complex

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SUNSHINE J C ET AL: "Poly(beta-Amino Ester)-Nanoparticle Mediated Transfection of Retinal Pigment Epithelial Cells In Vitro and In Vivo", PLOS ONE, vol. 7, no. 5, 21 May 2012 (2012-05-21), pages E37543-1 - 11, XP002746169, ISSN: 1932-6203, [retrieved on 20120521], DOI: 10.1371/JOURNAL.PONE.0037543 *

Also Published As

Publication number Publication date
CN105705140A (zh) 2016-06-22
JP2016535602A (ja) 2016-11-17
JP6454352B2 (ja) 2019-01-16
US20210054407A1 (en) 2021-02-25
CA2924013A1 (fr) 2015-05-14
EP3065711B8 (fr) 2024-10-16
EP3065711B1 (fr) 2024-09-04
WO2015069469A1 (fr) 2015-05-14
US20160251680A1 (en) 2016-09-01
EP3065711A1 (fr) 2016-09-14

Similar Documents

Publication Publication Date Title
EP2992097A4 (fr) Compositions et procédés
EP3008168A4 (fr) Cellules dérivées de cellules souches et compositions et procédés pour générer ces cellules
EP2951283A4 (fr) Compositions et procédés
EP3071694A4 (fr) Protéines cas9 mutantes
HK1214171A1 (zh) 賽尼克韋羅組合物及其製備和使用方法
EP3060561A4 (fr) Formulations de strigolactone et leurs utilisations
EP3062619A4 (fr) Compositions pesticides et procédés associés
EP3030266A4 (fr) Compositions topiques et procédés d'utilisation de celles-ci
EP3020778A4 (fr) Composition adhésive
EP3049429A4 (fr) Compositions et procédés utilisant des échafaudages de lysophosphatidylcholine
EP3003297A4 (fr) Formulations d'acamprosate, procédés d'utilisation de celles-ci, et combinaisons comprenant celles-ci
EP3060046A4 (fr) Compositions pesticides et procédés associés
EP3068500A4 (fr) Compositions d'engrais et procédés de fabrication et d'utilisation de celles-ci
EP3071036A4 (fr) Compositions pesticides et procédés associés
EP2992334A4 (fr) Nouveaux phosphatidylalcanols et leurs compositions
EP3013364A4 (fr) Compositions contre la tuberculose et méthodes d'utilisation de celles-ci
EP3060048A4 (fr) Compositions pesticides et procédés associés
EP3064513A4 (fr) Composition contenant un polyrotaxane
EP3041891A4 (fr) Matériaux et procédés
EP3060043A4 (fr) Compositions pesticides et procédés associés
EP3065729A4 (fr) Nouvelles formulations
EP2941273A4 (fr) Compositions et procédés de transfection de polynucléotides
EP3060047A4 (fr) Compositions pesticides et procédés associés
EP3033392A4 (fr) Composition mécano-réactive
EP2991949A4 (fr) Matières polycarbosiloxanes et procédés s'y rapportant

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160307

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: TAKARA BIO USA, INC.

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20170519

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 48/00 20060101ALI20170515BHEP

Ipc: A61K 47/00 20060101ALI20170515BHEP

Ipc: C12N 15/87 20060101ALI20170515BHEP

Ipc: A61K 9/00 20060101ALI20170515BHEP

Ipc: A61K 9/14 20060101AFI20170515BHEP

Ipc: A61K 9/51 20060101ALI20170515BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190625

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20231025

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20240325

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602014090824

Country of ref document: DE

Owner name: TAKARA BIO USA, INC., SAN JOSE, US

Free format text: FORMER OWNER: TAKARA BIO USA, INC., MOUNTAIN VIEW, CA, US

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602014090824

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PK

Free format text: BERICHTIGUNG B8

P01 Opt-out of the competence of the unified patent court (upc) registered

Free format text: CASE NUMBER: APP_49221/2024

Effective date: 20240829

RAP4 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: TAKARA BIO USA, INC.

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240905

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240905

Year of fee payment: 11